Table 2

Clinical and biological characteristics of the de novo pediatric AML cohort

Overall population (N = 237)Normal GATA2 expression (n = 82)High GATA2 expression (n = 155)P
Sex, n (%; n = 237) 
    Male 137 51 (37.2%) 86 (62.8%) .320* 
    Female 100 31 (31.0%) 69 (69.0%)  
Median age, y (n = 237) 9.6 8.9 9.8 .059† 
    < 2 y 38 18 (47.4%) 20 (52.6%) .071* 
    2-10 y 87 31 (35.6%) 56 (64.4%) .799* 
    > 10 y 112 33 (29.5%) 79 (70.5%) .116* 
Median WBC count, × 109/L (n = 216) 41.8 34.5 42.7 .276† 
    < 50 × 109/L 123 44 (35.8%) 79 (64.2%) .905* 
    > 50 × 109/L 93 34 (36.6%) 59 (63.4%)  
FAB, n (%; n = 226)    < .001* 
    M0 16 5 (31.3%) 11 (68.8%) .747* 
    M1 25 3 (12.0%) 22 (88.0%) .011* 
    M2 51 14 (27.5%) 37 (72.5%) .201* 
    M3 19 4 (21.1%) 15 (78.9%) .184* 
    M4 56 24 (42.9%) 32 (57.1%) .153* 
    M5 48 28 (58.3%) 20 (41.7%) < .001* 
    M6 3 1 (33.3%) 2 (66.7%) .953‡ 
    M7 8 0 (0%) 8 (100%) .053‡ 
Cytogenetic abnormalities, n (%; n = 222)    .001* 
    t(8;21)(q22;q22) 28 8 (28.6%) 20 (71.4%) .499* 
    inv(16)(p13q22) 27 12 (44.4%) 15 (55.6%) .233* 
    t(15;17)(q22;q21) 19 4 (21.1%) 15 (78.9%) .205* 
    11q23 translocations 50 30 (60.0%) 20 (40.0%) < .001* 
    Rare cytogenetics 58 12 (20.7%) 46 (79.3%) .044* 
    Normal cytogenetics (CN) 40 10 (25.0%) 30 (75.0%) .174* 
Other genetic abnormalities, n (%) 
    NPM1 mutations (n = 237) 17 3 (17.6%) 14 (82.4%) .127* 
    CEBPA mutations (n = 227) 16 2 (12.5%) 14 (87.5%) .056* 
        CEBPA single mutations (n = 227) 4 0 (0%) 4 (100%) .301‡ 
        CEBPA double mutations (n = 227) 12 2 (16.7%) 10 (83.3%) .227‡ 
    MLL-PTD (n = 237) 6 2 (33.3%) 4 (66.7%) 1.000‡ 
    FLT3-ITD (n = 237) 48 9 (18.7%) 39 (81.3%) .010* 
    WT1 mutations (n = 230) 20 2 (10.0%) 18 (90.0%) .015* 
    NRAS/KRAS mutations (n = 237) 41 17 (41.5%) 24 (58.5%) .310* 
    KIT mutations (n = 237) 18 7 (38.9%) 11 (61.1%) .691* 
    PTPN11 mutations (n = 237) 5 2 (40.0%) 3 (60.0%) 1.000‡ 
    High EVI1 expression (n = 237) 20 6 (30.0%) 14 (70.0%) .651* 
    High WT1 expression (n = 237) 176 42 (23.9%) 134 (76.1%) < .001* 
Overall population (N = 237)Normal GATA2 expression (n = 82)High GATA2 expression (n = 155)P
Sex, n (%; n = 237) 
    Male 137 51 (37.2%) 86 (62.8%) .320* 
    Female 100 31 (31.0%) 69 (69.0%)  
Median age, y (n = 237) 9.6 8.9 9.8 .059† 
    < 2 y 38 18 (47.4%) 20 (52.6%) .071* 
    2-10 y 87 31 (35.6%) 56 (64.4%) .799* 
    > 10 y 112 33 (29.5%) 79 (70.5%) .116* 
Median WBC count, × 109/L (n = 216) 41.8 34.5 42.7 .276† 
    < 50 × 109/L 123 44 (35.8%) 79 (64.2%) .905* 
    > 50 × 109/L 93 34 (36.6%) 59 (63.4%)  
FAB, n (%; n = 226)    < .001* 
    M0 16 5 (31.3%) 11 (68.8%) .747* 
    M1 25 3 (12.0%) 22 (88.0%) .011* 
    M2 51 14 (27.5%) 37 (72.5%) .201* 
    M3 19 4 (21.1%) 15 (78.9%) .184* 
    M4 56 24 (42.9%) 32 (57.1%) .153* 
    M5 48 28 (58.3%) 20 (41.7%) < .001* 
    M6 3 1 (33.3%) 2 (66.7%) .953‡ 
    M7 8 0 (0%) 8 (100%) .053‡ 
Cytogenetic abnormalities, n (%; n = 222)    .001* 
    t(8;21)(q22;q22) 28 8 (28.6%) 20 (71.4%) .499* 
    inv(16)(p13q22) 27 12 (44.4%) 15 (55.6%) .233* 
    t(15;17)(q22;q21) 19 4 (21.1%) 15 (78.9%) .205* 
    11q23 translocations 50 30 (60.0%) 20 (40.0%) < .001* 
    Rare cytogenetics 58 12 (20.7%) 46 (79.3%) .044* 
    Normal cytogenetics (CN) 40 10 (25.0%) 30 (75.0%) .174* 
Other genetic abnormalities, n (%) 
    NPM1 mutations (n = 237) 17 3 (17.6%) 14 (82.4%) .127* 
    CEBPA mutations (n = 227) 16 2 (12.5%) 14 (87.5%) .056* 
        CEBPA single mutations (n = 227) 4 0 (0%) 4 (100%) .301‡ 
        CEBPA double mutations (n = 227) 12 2 (16.7%) 10 (83.3%) .227‡ 
    MLL-PTD (n = 237) 6 2 (33.3%) 4 (66.7%) 1.000‡ 
    FLT3-ITD (n = 237) 48 9 (18.7%) 39 (81.3%) .010* 
    WT1 mutations (n = 230) 20 2 (10.0%) 18 (90.0%) .015* 
    NRAS/KRAS mutations (n = 237) 41 17 (41.5%) 24 (58.5%) .310* 
    KIT mutations (n = 237) 18 7 (38.9%) 11 (61.1%) .691* 
    PTPN11 mutations (n = 237) 5 2 (40.0%) 3 (60.0%) 1.000‡ 
    High EVI1 expression (n = 237) 20 6 (30.0%) 14 (70.0%) .651* 
    High WT1 expression (n = 237) 176 42 (23.9%) 134 (76.1%) < .001* 

Patients with high GATA2 expression are compared with patients with normal GATA2 expression. P values in bold indicate whether differences are significant at the level of .05.

*

χ2 test.

†

Mann-Whitney U test.

‡

Fisher exact test.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal